GlassScriptPhysician profile
Kimberly Scanlon
NPI 1073526463
$1,838.83
in general payments reported to CMS, 2019-2025
21 companies · $538 in 2025
The $538 reported for 2025 was more than what 75% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $38.73 · 2023: $484 · 2024: $778 · 2025: $538.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,800.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,800.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $372.47 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $305.02 | 2022-2025 | |
| Lilly USA, LLC | $172.20 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $164.55 | 2023-2025 | Farxiga, Airsupra |
| Abbvie INC. | $163.25 | 2023-2025 | Vraylar, Synthroid, Ubrelvy |
| Sequel Med Tech, LLC | $85.23 | 2025 | Twiist |
| Boehringer Ingelheim Pharmaceuticals, INC. | $77.25 | 2024-2025 | Jardiance, Synjardy, Tradjenta |
| Exact Sciences Corporation | $68.40 | 2024-2025 | Cologuard Collection Kit |
| Amgen INC. | $64.97 | 2023-2025 | Evenity, Otezla, Repatha |
| Dexcom, INC. | $62.54 | 2023-2024 | Dexcom G6 Transmitter |
| Glaxosmithkline, LLC. | $55.10 | 2023-2024 | Shingrix, Arexvy |
| Xeris Pharmaceuticals, INC. | $47.37 | 2024 | Gvoke Hypopen |
| Abbott Laboratories | $34.79 | 2024-2025 | Freestyle Libre 3 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $30.47 | 2023-2024 | Xifaxan |
| Kyowa Kirin, INC. | $27.21 | 2023 | Crysvita |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amphastar Pharmaceuticals, INC. | $22.12 | 2024 | |
| Insulet Corporation | $20.16 | 2023 | Omnipod |
| Tandem Diabetes Care, INC. | $19.00 | 2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Amneal Pharmaceuticals LLC | $18.69 | 2024 | Unithroid |
| Ibsa Pharma INC. | $17.30 | 2025 | Flector, Licart, Tirosint |
| Theracosbio, LLC | $10.74 | 2024 | Brenzavvy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kimberly Scanlon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.